Avoiding artificiality in teleconsultations.

J Telemed Telecare

A and E Services, North West London Hospitals Trust, Central Middlesex Hospital, London, UK.

Published: January 2002

The ideal videoconferencing environment would produce the minimum feeling of artificiality for its users. We assessed nurse and patient perceptions of artificiality by varying the technical and operational procedures for telemedicine in a minor injuries unit. Twenty-five patients and eight emergency nurse practitioners (ENPs) participated in simulated teleconsultations under a variety of different conditions and completed a Likert-scale survey. There was a close correlation between the ENPs' ratings and the patients' ratings for the various factors (r > 0.99). In relation to technical factors, a flicker-free television screen and the user being seated close to the screen were preferred. Similarly, in relation to operational procedures, an initial explanation of telemedicine, introductions and adequate preparation were also preferred. The study suggests that careful attention to technical specifications and operational procedures can reduce the perceived artificiality of teleconsultations.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1357633X010070S116DOI Listing

Publication Analysis

Top Keywords

operational procedures
12
artificiality teleconsultations
8
avoiding artificiality
4
teleconsultations ideal
4
ideal videoconferencing
4
videoconferencing environment
4
environment produce
4
produce minimum
4
minimum feeling
4
feeling artificiality
4

Similar Publications

Background: Microbiota of the distal part of the intestine produces Urolithin A (Uro A) as a derivative of ellagitannins hydrolysis. Recently, the mitophagy, anti-inflammatory, and antioxidant properties of Uro A have focused more attention on its probable beneficial effects on neurodegenerative states. The purpose of this research was to study the impact of Uro A on the histopathology of the cerebellum in a rat model of streptozotocin-induced Alzheimer's disease.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Pentara Corporation, Salt Lake City, UT, USA.

Background: Alzheimer's disease (AD) presents unique challenges in clinical trials involving small molecules. Multifaceted issues plague such trials, emphasizing susceptibility to fraud from clinical sites and "professional patients". The relative ease of simulating Alzheimer's diagnosis, coupled with inadequate oversight by Contract Research Organizations (CROs), creates fertile ground for deceptive practices.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

iCBR - Coimbra Institute for Clinical and Biomedical Research, Faculty of Medicine, University of Coimbra, Coimbra, Coimbra, Portugal; Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, University of Coimbra, Coimbra, Coimbra, Portugal; CIBB - Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Coimbra, Portugal; Institute of Interdisciplinary Research (IIIUC), University of Coimbra, Coimbra, Coimbra, Portugal; CNC-UC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Coimbra, Portugal.

Background: Cardiometabolic diseases, such as type 2 diabetes, hypertension, dyslipidemia or obesity, constitute major causes of mortality and morbidity worldwide, especially among middle-aged individuals. The increasing incidence and association with aging and lifestyle, render the cardiometabolic diseases a societal concern. This is further reinforced by their association with an increased risk of cognitive impairment and neurodegenerative diseases (namely dementia and Alzheimer's disease (AD)).

View Article and Find Full Text PDF

Background: As Japan experiences a super-ageing society and caregiver manpower decreases, interest in the use of communication robots for active dementia care rises. In the U.S.

View Article and Find Full Text PDF

Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

December 2024

Westport, CT, USA.

Background: A 73-year-old female with a 3 year history of Alzheimer's disease was treated within the protocol of The Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study (ACIST), an IRB approved clinical study registered with clinicaltrials.gov NCT03724136.

Method: The procedure consists of bone marrow aspiration, cell separation using an FDA cleared class 2 device, and intravenous and intranasal administration of the stem cell fraction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!